Larry Ramer

Larry Ramer

InvestorPlace Contributor

Larry Ramer has more than 15 years of experience in business journalism. He has worked for Globes, Israel’s most widely read business newspaper, as well as The Jerusalem Post and theflyonthewall.

Mr. Ramer’s expansive knowledge of politics enables him to provide valuable insights into how politics can affect stocks. He also focuses on contrary investing and specializes in the renewable energy and consumer discretionary sectors.

Among his highly successful, contrarian picks have been Super Micro Computer, Intel, and MGM Resorts.

You can reach him on StockTwits at @larryramer and learn more about his stock-picking record at his TipRanks profile.

Recent Articles

The Decline of AT&T Has Created a Good Buying Opportunity

By Larry Ramer, InvestorPlace Contributor

AT&T will benefit meaningfully from its recent deals, making T stock appealing to conservative investors following its decline.

3 Stocks To Buy After European Stocks Hit a Record

By Larry Ramer, InvestorPlace Contributor

After European stocks reached record levels recently, the continent continues to have many important positive catalysts, including its green stimulus plan.

Bionano Stock Will Soar as the Company’s Diagnostic System Catches On

By Larry Ramer, InvestorPlace Contributor

As more payors reimburse labs for using Bionano's Saphyr device, the company's financial results will improve, lifting BNGO stock.

Avoid Unproven Meta Materials for Now

By Larry Ramer, InvestorPlace Contributor

Meta's new products may not pan out, and meme stocks are likely to continue to weaken, making MMAT stock unattractive.

This Is Why Carnival Stock Continues To Face Big Risks

By Larry Ramer, InvestorPlace Contributor

The outlook of CCL stock has rebounded, but investors should still sell the shares, given the large risks still faced by Carnival.

Wait for a Pullback Before Pulling the Nvidia Stock Trigger

By Larry Ramer, InvestorPlace Contributor

With NVDA stock likely to take some punches relatively soon, investors should avoid the shares for now. But be prepared to buy it on dips.

Cassava Sciences Stock Is a Buy on the Strength of a Promising Alzheimer’s Drug

By Larry Ramer, InvestorPlace Contributor

Skeptics are wrong about Cassava's Alzheimer's drug, as the drug's data is superb. Long-term investors should buy SAVA stock.

Palantir Stock Looks More Overvalued by the Day as Costs Keep Rising

By Larry Ramer, InvestorPlace Contributor

PLTR stock has a huge valuation that does not seem to be justified by the company's financial results or technology.

Paysafe Stock Is Probably the Best of the Upstart Fintechs Out There

By Larry Ramer, InvestorPlace Contributor

PSFE stock is the type of underestimated, little-noticed, high-quality name that usually handsomely reward long-term investors.

Tilray Stock Is Probably Overvalued At This Price

By Larry Ramer, InvestorPlace Contributor

TLRY stock currently reflects unrealistic assumptions about its growth and about the chances of legalization in the United States.

Load More